drug approvals

This past May, the FDA approved the targeted therapy alpelisib (Piqray) to treat certain hormone receptor-positive, HER2-negative breast cancers in postmenopausal women and in men. Up to 40 percent of people with metastatic hormone receptor-positive, HER2-negative breast cancer could be eligible to get the treatment, which targets a mutation on the PIK3CA gene. Join us... Continue Reading →